Xenon Pharmaceuticals raises $29.2M under equity offering program
Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills
Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds
Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall
Global M&A By the Numbers: Q1 2022
Xenon Pharmaceuticals Inc. said it raised about $29.2 million as of July 3 under an equity offering program.
The proceeds are from the sale of 3,440,000 common shares, the Burnaby, British Columbia-based biopharmaceutical company said.
In May, Xenon entered a sales agreement with Stifel Nicolaus & Co. Inc. for the sale of up to $30 million of common shares.